Page 295 - Haematologica April 2020

mRNA-based therapy for hemophilia A
Blood. 2011;117(3):798-807.
26. Pipe SW, Eickhorst AN, McKinley SH,
Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonprote- olytic inactivation of factor VIIIa in vivo. Blood. 1999;93(1):176-183.
27. Kaufman RJ, Wasley LC, Davies MV, et al. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989;9(3):1233-1242.
28. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clot- ting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther. 1993;4(3):259-272.
29. Hoeben RC, Fallaux FJ, Cramer SJ, et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood. 1995;85(9):2447-2454.
30. Dorner AJ, Bole DG, Kaufman RJ. The rela- tionship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol. 1987;105(6 Pt 1):2665-2674.
31. Miao HZ, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004;103(9): 3412-3419.
32. Swaroop M, Moussalli M, Pipe S, Kaufman R. Mutagenesis of a potential immunoglob- ulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem. 1997;272:24121-24124.
33. Zhang B, McGee B, Yamaoka JS, et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood. 2006;107(5):1903-1907.
34. Zhou Z, Dang Y, Zhou M, et al. Codon usage is an important determinant of gene
expression levels largely through its effects on transcription. Proc Natl Acad Sci U S A. 2016;113(41):E6117-E6125.
35. Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine con- tent increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6):e180.
36. den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to base- line FVIII activity levels. Haemophilia. 2011;17(1):41-44.
37. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limita- tions of current prophylactic regimens. Blood. 2015;125(13):2038-2044.
38. Farelli JD, Asrani KH, Isaacs C, et al. Leveraging rational protein engineering to improve mRNA therapeutics. Nucleic Acid Ther. 2018;28(2):74-85.
39. Siner JI, Samelson-Jones BJ, Crudele JM, et al. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. JCI Insight. 2016;1(16):e89371.
40. Nguyen GN, George LA, Siner JI, et al. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A. J Thromb Haemost. 2017;15(1):110-121.
41. Monaghan M, Wakabayashi H, Griffiths A, Wintermute J, Fay PJ. Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit. Thromb Haemost. 2014;112(3):495-502.
42. Shahani T, Lavend'homme R, Luttun A, et al. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood. 2010;115(23):4902-4909.
43. Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood. 2016;128(1):104-109.
44. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055.
45. Reipert BM, Ahmad RU, Turecek PL, et al. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost. 2000;84(5):826-832.
46. Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing anti- body protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630.
47. VandenDriessche T, Collen D, Chuah MK. Gene therapy for the hemophilias. J Thromb Haemost. 2003;1(7):1550-1558.
48. Ing M, Gupta N, Teyssandier M, et al. Immunogenicity of long-lasting recombi- nant factor VIII products. Cell Immunol. 2016;301:40-48.
49. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5(7):1383-1390.
50. Dahlman JE, Barnes C, Khan O, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol. 2014;9(8):648-655.
51. Matsui H, Hegadorn C, Ozelo M, et al. A microRNA-regulated and GP64-pseudo- typed lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A. Mol Ther. 2011;19(4):723- 730.
haematologica | 2020; 105(4)
1137